Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bacterici...

Descripción completa

Detalles Bibliográficos
Autores principales: McNeil, Lisa K., Donald, Robert G. K., Gribenko, Alexey, French, Roger, Lambert, Nathaniel, Harris, Shannon L., Jones, Thomas R., Li, Sheng, Zlotnick, Gary, Vogel, Ulrich, Claus, Heike, Abad, Raquel, Vazquez, Julio A., Borrow, Ray, Findlow, Jamie, Taha, Muhamed-Kheir, Deghmane, Ala-Eddine, Caugant, Dominique A., Kriz, Paula, Musilek, Martin, Wang, Xin, Vuong, Jeni, Mayer, Leonard W., Pride, Michael W., Jansen, Kathrin U., Anderson, Annaliesa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850321/
https://www.ncbi.nlm.nih.gov/pubmed/29535195
http://dx.doi.org/10.1128/mBio.00036-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850321/
https://www.ncbi.nlm.nih.gov/pubmed/29535195
http://dx.doi.org/10.1128/mBio.00036-18

Ejemplares similares